Immunoprecise Antibodies Ltd.'s subsidiary, Talem Therapeutics LLC, has shared promising results of a new study conducted by the National Institute of Allergy and Infectious Diseases (NIAID) showing continued resilience of Polytope TATX-03 in broadly neutralizing SARS-CoV-2 variants, including two omicron sublineages that had not been previously tested.

Following a research program to identify inhibitors of protein kinases TBK1 and IKK-ε, Domainex Ltd. has nominated DMXD-011 as a preclinical drug candidate.

Researchers from Centessa Pharmaceuticals plc presented preclinical data for LB-101, a novel first-in-class immunotherapy targeting solid tumors.

Using a two-drug combination, researchers at the University of California at San Francisco (UCSF) have been able to achieve brain-specific inhibition of several kinases.

Seoul National University has patented chaperone protein DnaK (HSP70) inhibitors acting as antineoplastic enhancing agents reported to be useful for the treatment of cancer.

New and updated preclinical data presented at the Annual Congress of the European Society for Medical Oncology in Paris, including: Enlivex, GT Biopharma, Immatics, SQZ Biotechnologies.